Evolus has secured exclusive U.S. distribution rights to Profhilo, an IBSA hyaluronic acid injectable biostimulator, under a 15-year licensing agreement with no upfront payment. The deal signals Evolus's strategy to broaden its injectables footprint beyond Jeuveau (neuromodulator) and into the growing biostimulator category, where practices increasingly stack HA-based products alongside toxin and filler for volumization and collagen remodeling.
Injectables
Evolus Secures Exclusive U.S. License for Profhilo — 15-Year Term, No Upfront Fee
Injectable biotech adds hyaluronic acid biostimulator to portfolio; no upfront payment signals confidence in market adoption.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Evolus adds Profhilo to injectables portfolio under 15-year exclusive U.S. license with no upfront fee.
Profhilo's mechanism—high-concentration HA with minimal cross-linking, designed for superficial dermal placement and hydration-driven collagen stimulation—positions it as a complement to PLLA (Sculptra) and CaHA (Radiesse) in the biostimulator ladder. For Evolus, the zero-upfront structure reflects confidence in Profhilo's adoption trajectory and suggests aggressive go-to-market pricing through Evolus Rewards to capture medspa share from Allergan and Galderma's established HA portfolios.
Source: original report ↗
Frequently asked questions
What is Profhilo and how does it work as a biostimulator?
Profhilo is a high-concentration hyaluronic acid injectable biostimulator with minimal cross-linking, designed for superficial dermal placement. It works by delivering hydration-driven collagen stimulation, making it a complement to other biostimulators like Sculptra (PLLA) and Radiesse (CaHA) in treatment protocols.
Why did Evolus structure the Profhilo deal with no upfront payment?
The zero-upfront fee structure signals Evolus's confidence in Profhilo's market adoption and revenue potential. This approach allows Evolus to minimize financial risk while betting on aggressive go-to-market pricing and market share capture from competitors like Allergan and Galderma.
How long is Evolus's exclusive license for Profhilo in the U.S.?
Evolus holds a 15-year exclusive U.S. distribution agreement for Profhilo, giving the company over a decade to establish market dominance in the hyaluronic acid biostimulator category.
What injectables does Evolus now offer after the Profhilo deal?
Evolus now offers Jeuveau (neuromodulator) and Profhilo (HA biostimulator), expanding its portfolio from toxin into the growing biostimulator category where practices stack multiple modalities for volumization and collagen remodeling.
How does Profhilo fit into a medspa treatment ladder?
Profhilo sits alongside PLLA (Sculptra) and CaHA (Radiesse) as part of a tiered biostimulator approach, allowing practices to offer patients multiple collagen-stimulating options with different mechanisms and longevity profiles for customized anti-aging protocols.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.